Our study provides further insight into this ongoing debate by emphasizing the potential advantages of ATR1 blockers and ACE inhibitors in managing heart failure in diabetes, and our findings reinforce the importance of optimizing RAS-targeted therapies to improve cardiac outcomes in diabetic patients. Here, AGTR1 is linked to diabetes mellitus.